PhotoCure ASA's efforts to obtain U.S. approval for its Metvix photodynamic therapy as a treatment for basal-cell carcinoma hit another roadblock last week, as FDA officials ruled that the clinical data submitted in its new drug application were insufficient for approval. (BioWorld International)

PhotoCure ASA's efforts to obtain U.S. approval for its Metvix photodynamic therapy as a treatment for basal-cell carcinoma hit another roadblock last week, as FDA officials ruled that the clinical data submitted in its new drug application were insufficient for approval. (BioWorld International)

For analysts eagerly anticipating developments with Antegren, Elan Corp. plc's multiple sclerosis drug, the news last week that Prialt, its first pain product, gained a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use was a pleasant sideshow. (BioWorld International)

For analysts eagerly anticipating developments with Antegren, Elan Corp. plc's multiple sclerosis drug, the news last week that Prialt, its first pain product, gained a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use was a pleasant sideshow. (BioWorld International)